Construction of novel immune-related signature for prediction of pathological complete response to neoadjuvant chemotherapy in human breast cancer
Open Access
- 1 January 2014
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 25 (1) , 100-106
Abstract
The aim of this study was to construct a novel prediction model for the pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) using immune-related gene expression data. DNA microarray data were used to perform a gene expression analysis of tumor samples obtained before NAC from 117 primary breast cancer patients. The samples were randomly divided into the training (n = 58) and the internal validation (n = 59) sets that were used to construct the prediction model for pCR. The model was further validated using an external validation set consisting of 901 patients treated with NAC from six public datasets. The training set was used to construct an immune-related 23-gene signature for NAC (IRSN-23) that is capable of classifying the patients as either genomically predicted responders (Gp-R) or non-responders (Gp-NR). IRSN-23 was first validated using an internal validation set, and the results showed that the pCR rate for Gp-R was significantly higher than that obtained for Gp-NR (38 versus 0%, P = 1.04E−04). The model was then tested using an external validation set, and this analysis showed that the pCR rate for Gp-R was also significantly higher (40 versus 11%, P = 4.98E−23). IRSN-23 predicted pCR regardless of the intrinsic subtypes (PAM50) and chemotherapeutic regimens, and a multivariate analysis showed that IRSN-23 was the most important predictor of pCR (odds ratio = 4.6; 95% confidence interval = 2.7–7.7; P = 8.25E−09). The novel prediction model (IRSN-23) constructed with immune-related genes can predict pCR independently of the intrinsic subtypes and chemotherapeutic regimens.Keywords
Funding Information
- Knowledge Cluster Initiative of the Ministry of Education, Culture, Sports, Science
- Technology of Japan
- Sysmex Corporation
This publication has 25 references indexed in Scilit:
- Predictive Biomarkers in Breast Cancer: Their Value in Neoadjuvant ChemotherapyCancer Investigation, 2012
- Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patientsBreast Cancer Research and Treatment, 2012
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer SubtypesJournal of Clinical Oncology, 2012
- A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid TumorsClinical Cancer Research, 2012
- Multifactorial Approach to Predicting Resistance to AnthracyclinesJournal of Clinical Oncology, 2011
- Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancersCancer, 2011
- Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast CancerJNCI: Journal of the National Cancer Institute, 2010
- Effect of training-sample size and classification difficulty on the accuracy of genomic predictorsBreast Cancer Research, 2010
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast CancerJournal of Clinical Oncology, 2010
- Primary Systemic Therapy of Breast CancerThe Oncologist, 2006